Nav: Home

Medication against schizophrenia inhibits pancreatic cancer

September 07, 2016

Cancer of the pancreas is an extremely aggressive disease with a dismal prognosis. The number of cases that is newly diagnosed with this type of cancer each year is almost the same as the one of people who succumb to it. While advances in prevention, early detection and treatment have led to a drop in mortality rates in most other cancer types, a growing number of people in Germany and world-wide develop pancreatic cancer and die from it.

"The tumors do not cause any signs or symptoms for a long time and are therefore diagnosed late," says Jörg Hoheisel from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg. "In addition, the tumor biology is very aggressive, i.e., the cancer starts spreading metastases early on. And to make things worse, pancreatic cancer rapidly develops resistance against available chemotherapy drugs."

Therefore, scientists are making great efforts to identify novel molecular targets that can be attacked to fight pancreatic cancer. Hoheisel and his colleagues from Heidelberg, Tübingen, Liverpool, Verona, Toronto and Montreal undertook a large-scale analysis of gene activities in 195 pancreatic cancer cases. "We leveraged quantitative and computational biology approaches that we have established in order to identify genes that may play a central role in several pancreatic cancer-relevant signaling pathways among almost 3,000 genes that exhibited abnormally high or low activities" said Riazalhosseini of McGill University who co-led the study with Hoheisel., In this way, they identified the dopamine receptor DRD2. The DRD2 gene was significantly more active in cancer cells than in healthy pancreatic cells, and the levels of DRD2 receptor protein found in the cancer cells were four times the normal.

Blocking the dopamine receptor inhibits cancer growth

The dopamine receptor mediates the effect of the dopamine neurotransmitter in the brain. Dopamine is an important brain chemical that increases motivation and drive. How can a receptor protein that is known to clinicians primarily for its role in schizophrenia and psychotic disorders influence the malignant characteristics of cancer cells? The researchers pursued this question in pancreatic cancer cell lines in which they had turned off the DRD2 gene. They observed that these cells in fact grew more slowly and formed smaller tumors when transferred to mice.

DRD2 is a key molecule in many psychotic diseases and is therefore targeted by numerous psychopharmaceutical agents. Drugs that block the function of DRD2 ("dopamine antagonists") have been available since the 1950s. Among them is the antipsychotic pimozide. Using this substance, the investigators collaborating with Hoheisel succeeded in substantially slowing down the growth and impeding the mobility of pancreatic cancer cell lines.

The researchers transferred human pancreatic cancer cells to mice and allowed them to grow into tumors. After treating the animals with another dopamine antagonist - haloperidol, a medication that is often prescribed to treat schizophrenia - they developed smaller tumors and, more importantly, fewer metastases than untreated animals.

"We do not know yet whether haloperidol or related medications have the same effect in pancreatic cancer patients as they have in tumor cells and mice," Hoheisel said. He added as an interesting observation that schizophrenia patients, who are treated mostly with dopamine antagonists, have a lower rate of solid tumors on the whole than the general population. It is therefore possible that the cancer-inhibiting effect might not be restricted to the pancreas.

The DKFZ researchers now plan to examine in a study with pancreatic cancer patients whether drugs from the group of dopamine antagonists have a favorable effect on the course of the disease. For this, they will continue collaborating closely with Markus W. Büchler from Heidelberg University Hospital and the colleagues at McGill University in Montreal with the goal of treating pancreatic cancer patients. "We are very lucky to have come across established medications. This should make the required and laborious safety examinations easier," said Hoheisel.

Dopamine receptor protects cancer cells from biochemical stress

The DKFZ researchers additionally wanted to gain an understanding of the molecular mechanisms by which the dopamine receptor drives cancer growth. Normally, DRD2 prevents cells from experiencing biochemical stress via a crucial intracellular signaling molecule called cAMP. After blocking DRD2, the rapidly dividing cancer cells are particularly exposed to this kind of stress. This leads to a breakdown of the cell division cycle and then to cell self-destruction (apoptosis).

The investigators found higher-than-normal activity of the DRD2 gene already in chronic pancreatitis, which is considered to be a precancerous stage of pancreatic cancer. Other authors have also described increased activity levels of the DRD2 gene in cancer stem cells. Hoheisel and colleagues therefore think that this alteration occurs at a very early stage of cancer development.
-end-
Pouria Jandaghi, Hamed S. Najafabadi, Andrea S. Bauer, Andreas I. Papadakis, Matteo Fassan, Anita Hall, Anie Monast, Magnus von Knebel Doeberitz, John P. Neoptolemos, Eithne Costello, William Greenhalf, Aldo Scarpa, Bence Sipos, Daniel Auld, Mark Lathrop, Morag Park, Markus W. Büchler, Oliver Strobel, Thilo Hackert, Nathalia A. Giese, George Zogopoulos, Veena Sangwan, Sidong Huang, Yasser Riazalhosseini, Jörg D. Hoheisel: DRD2 is critical for pancreatic cancer and promises pharmacological therapy by already established antagonists. Gastroenterology 2016, DOI 10.1053/j.gastro.2016.08.040

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Cancer Consortium (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Contact:

Dr. Stefanie Seltmann
Head of Press and Public Relations
German Cancer Research Center
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2854
F: +49 6221 42 2968
presse@dkfz.de

Dr. Sibylle Kohlstädt
Press and Public Relations
German Cancer Research Center
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2843
F: +49 6221 42 2968
Email: presse@dkfz.de

German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.